1. Indications:

Mobonib (Mobocertinib) 40 mg is indicated for the treatment of:

• Locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.

2. Pharmacology:

Mobonib (Mobocertinib) 40 mg exerts its pharmacological effects by selectively inhibiting the activity of mutant forms of the epidermal growth factor receptor (EGFR), particularly those with exon 20 insertion mutations. By blocking these mutated receptors, Mobonib inhibits downstream signaling pathways involved in cancer cell proliferation and survival, ultimately leading to tumor regression and inhibition of cancer progression.

3. Dosage and Administration:

The recommended dosage of Mobonib (Mobocertinib) 40 mg is one tablet taken orally once daily, with or without food. Treatment should continue until disease progression, unacceptable toxicity, or other treatment discontinuation criteria are met. Dose adjustments or discontinuation may be necessary based on individual patient response and tolerability.

4. Interaction:

Mobonib (Mobocertinib) 40 mg may interact with other medications, including:

• Strong CYP3A4 inhibitors or inducers: Co-administration with drugs that affect CYP3A4 metabolism may alter the plasma concentration of Mobonib.
• Acid-reducing agents: Concurrent use of proton pump inhibitors (PPIs) or H2-receptor antagonists may decrease the absorption of Mobonib, potentially reducing its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Mobonib (Mobocertinib) 40 mg may include:

• Diarrhea
• Rash
• Nausea
• Fatigue
• Vomiting
• Elevated liver enzymes

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Mobonib (Mobocertinib) 40 mg, patients should be aware of the following precautions:

• Mobonib may cause interstitial lung disease (ILD) or pneumonitis, which can be fatal. Patients should be monitored closely for respiratory symptoms and undergo regular imaging studies during treatment.
• Hepatotoxicity, including liver function abnormalities, has been reported with Mobonib. Liver function tests should be performed before starting treatment and periodically thereafter.
• Mobonib may prolong the QT interval, increasing the risk of arrhythmias. Electrocardiograms (ECGs) should be monitored regularly, especially in patients with pre-existing cardiac conditions.

7. Overdose Effects:

In case of overdose with Mobonib (Mobocertinib) 40 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Mobonib overdose, and patients should seek immediate medical attention if overdose is suspected.